Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 775.45 USD -2.47% Market Closed
Market Cap: 734.9B USD

ROE
Return on Equity

77.7%
Current
65%
Average
3.5%
Industry

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
77.7%
=
Net Income
11.1B
/
Equity
14.3B

ROE Across Competitors

Country Company Market Cap ROE
US
Eli Lilly and Co
NYSE:LLY
734.9B USD
78%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
366.6B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
88%
CH
Roche Holding AG
SIX:ROG
208.1B CHF
27%
CH
Novartis AG
SIX:NOVN
188.4B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
158.5B GBP
20%
US
Merck & Co Inc
NYSE:MRK
199B USD
39%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
US
Pfizer Inc
NYSE:PFE
137.5B USD
9%
FR
Sanofi SA
PAR:SAN
103.4B EUR
17%

Eli Lilly and Co
Glance View

Economic Moat
Wide
Market Cap
734.9B USD
Industry
Pharmaceuticals

Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.

LLY Intrinsic Value
357.1 USD
Overvaluation 54%
Intrinsic Value
Price
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
77.7%
=
Net Income
11.1B
/
Equity
14.3B
What is the ROE of Eli Lilly and Co?

Based on Eli Lilly and Co's most recent financial statements, the company has ROE of 77.7%.

Back to Top